Institutional Investors Are Buying Radius Health (NASDAQ:RDUS)

Radius Health, Inc. (NASDAQ:RDUS) Logo

Sentiment for Radius Health (NASDAQ:RDUS)

Radius Health (NASDAQ:RDUS) institutional sentiment increased to 1.72 in 2018 Q2. Its up 0.93, from 0.79 in 2018Q1. The ratio is better, as 67 institutional investors increased or started new equity positions, while 39 sold and decreased their stakes in Radius Health. The institutional investors in our partner’s database now own: 51.82 million shares, down from 54.99 million shares in 2018Q1. Also, the number of institutional investors holding Radius Health in their top 10 equity positions was flat from 3 to 3 for the same number . Sold All: 19 Reduced: 20 Increased: 44 New Position: 23.

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. The company has market cap of $721.35 million. The Company’s product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. It currently has negative earnings. The firm is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer.

The stock decreased 2.94% or $0.48 during the last trading session, reaching $15.84. About 746,215 shares traded. Radius Health, Inc. (NASDAQ:RDUS) has declined 47.36% since December 8, 2017 and is downtrending. It has underperformed by 62.98% the S&P500.

Analysts await Radius Health, Inc. (NASDAQ:RDUS) to report earnings on March, 7. They expect $-1.27 earnings per share, up 20.13 % or $0.32 from last year’s $-1.59 per share. After $-1.09 actual earnings per share reported by Radius Health, Inc. for the previous quarter, Wall Street now forecasts 16.51 % negative EPS growth.

Mpm Asset Management Llc holds 45.65% of its portfolio in Radius Health, Inc. for 4.00 million shares. Bb Biotech Ag owns 6.20 million shares or 5.28% of their US portfolio. Moreover, Senzar Asset Management Llc has 5.15% invested in the company for 60,521 shares. The New York-based Healthcor Management L.P. has invested 1.89% in the stock. Rock Springs Capital Management Lp, a Maryland-based fund reported 1.13 million shares.

Since January 1, 0001, it had 4 insider buys, and 0 insider sales for $7.31 million activity.

Radius Health, Inc. (NASDAQ:RDUS) Ratings Coverage

Ratings analysis reveals 100% of Radius Health’s analysts are positive. Out of 3 Wall Street analysts rating Radius Health, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $47 while the high is $60. The stock’s average target of $52 is 228.28% above today’s ($15.84) share price. RDUS was included in 5 notes of analysts from June 11, 2018. Bank of America maintained it with “Buy” rating and $47 target in Wednesday, July 25 report. Morgan Stanley maintained it with “Overweight” rating and $57 target in Thursday, October 11 report. JP Morgan maintained it with “Overweight” rating and $59 target in Monday, July 23 report. As per Monday, June 11, the company rating was maintained by JP Morgan. The stock of Radius Health, Inc. (NASDAQ:RDUS) earned “Overweight” rating by JP Morgan on Friday, November 2.

More notable recent Radius Health, Inc. (NASDAQ:RDUS) news were published by: which released: “Radius Health Announces Third Quarter 2018 Operating Results and Financial Guidance for FY 2018 and FY 2019 – Nasdaq” on November 01, 2018, also with their article: “Why Is Radius Health (RDUS) Down 11.8% Since Last Earnings Report? –” published on September 06, 2018, published: “Radius Health, Inc. 2018 Q2 – Results – Earnings Call Slides – Seeking Alpha” on August 07, 2018. More interesting news about Radius Health, Inc. (NASDAQ:RDUS) were released by: and their article: “Radius Health, Inc. 2018 Q3 – Results – Earnings Call Slides – Seeking Alpha” published on November 01, 2018 as well as‘s news article titled: “Daily Biotech Pulse: FDA Nod For Mallinckrodt’s Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results – Benzinga” with publication date: November 15, 2018.

Radius Health, Inc. (NASDAQ:RDUS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.